Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of age

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500883-37-00

Acronym

216156 (NGG-001)

Enrollment

592

Registered

2023-05-03

Start date

2023-10-02

Completion date

2025-05-21

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This FTiH-PoC study aims to provide an early evaluation of the efficacy of the investigational vaccine as there are no established immunogenicity correlates of protection against infections caused by Neisseria gonorrhoeae.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Countries

France, Germany, Spain

Outcome results